RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $430 to $470.
RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $430 to $470.